Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia.
- 24 April 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 59 (1) , 53-58
- https://doi.org/10.1111/j.1600-0609.1997.tb00959.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerPublished by Elsevier ,1996
- A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disordersBritish Journal of Haematology, 1996
- Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcomaEuropean Journal Of Cancer, 1996
- Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.The Journal of Experimental Medicine, 1996
- The problem of thrombocytopenia and its managementAnti-Cancer Drugs, 1995
- Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpICell, 1994
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesisNature, 1994
- Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivoNature, 1994
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994
- Regulation of megakaryocytopoiesisThe International Journal of Cell Cloning, 1993